BIBEONE@EC2610A

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

01024

00700

06862

03690

09618

06160

09888

09696

02015

00020

As of noon, the three major indices of the Hong Kong stock market rose collectively, with the Hang Seng Index approaching the 24,993-point mark and the Hang Seng Tech Index returning above 4,811 points. Market sentiment is relatively stable, with heavyweight and tech stocks resonating upward. In terms of sectors, the restaurant and retail industries performed strongly, with Haidilao leading the midday gains at 6.47%, and core assets such as Meituan and BYD leading in trading volume. Investors are closely monitoring macroeconomic data and performance guidance from core sectors, with overall market trading remaining active

- As of March 27, 2026, Hong Kong’s stock market indices showed positive movement, with the Hang Seng Index at 24,993.64, up 0.55%.  
- Notable performances included Haidilao, which rose 6.47%, reflecting recovering demand in the restaurant sector, while macroeconomic indicators are drawing investor focus.  
- The trading volume highlighted major players, including Meituan and Tencent, with respective figures of 62.41 billion HKD and 59.09 billion HKD amid mixed sector performance.

Market Heartbeat

KUAISHOU-W

TENCENT

HAIDILAO

MEITUAN

JD-SW

BEONE MEDICINES

BIDU-SW

TIANQI LITHIUM

LI AUTO-W

SENSETIME-W

Hong Kong Stock Midday Review | Hang Seng Index Approaches 25,000 Points, Strong Performance in Dining Retail with Haidilao Up 6.47%

688235

BeiGene's total revenue for 2025 increased by 40.2% year-on-year, with net product sales amounting to $5.282 billion, up 39.8% year-on-year. Sales of its core product, Brukinsa, reached $3.928 billion globally, a year-on-year increase of 48.6%, maintaining its leading global position among BTK inhibitors. Tislelizumab sales were $737 million, up 18.8% year-on-year

- BeiGene achieved a milestone in 2025 with a net profit of $287 million, reversing a loss of $645 million from the previous year.  
- Total revenue reached $5.343 billion, a 40.2% increase, driven by strong sales of core products and improved cash flow, totaling $4.548 billion by year-end.  
- The company also made significant progress with its pipeline, gaining FDA priority review for a new treatment for blood cancers and advancing its product offerings in solid tumors.

Wallstreetcn

BeOne Medicines

Achieves Annual Profitability for the First Time! BeiGene Reports 2025 Net Profit of $287 Million, Revenue Surges 40% to $5.34 Billion | Earnings Watch

512010

560600

512290

159992

513700

520880

159859

159892

516930

159837

159316

588250

513120

520690

159506

516500

588130

BEONE MEDICINES expects revenue of USD 5.343 billion in 2025, a year-on-year increase of 40.2%; net profit is expected to be USD 287 million, compared to a net loss of USD 645 million in the same period last year. Risk warning: The market has risks, and investment should be cautious. This article does not constitute personal investment advice

华尔街见闻资讯

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

Beijing Beone Medicines: Revenue of USD 5.343 billion in 2025, a year-on-year increase of 40.2%; net profit of USD 287 million, compared to a net loss of USD 645 million in the same period last year

SBIO

ARKG

BGNE

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

Tip Ranks

iShares US Pharma

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VG Health

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Beigene

Direxion S&P Biotech Bull 3X

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

BeOne Medicines Ltd has reported the results of its Fifth Amended and Restated 2018 Employee Share Purchase Plan, where 4,431 employees purchased 57,023 ADSs at a 15% discount. This represents about 0.05% of the company's issued capital. The plan aims to enhance employee ownership without significant dilution, with 2,438,481 shares available for future grants. The latest analyst rating for BeOne Medicines (HK:6160) is a Hold with a price target of HK$200.00. The company operates in the biopharmaceutical sector and is listed in Hong Kong.

BeOne Medicines Updates on Employee Share Purchase Plan Uptake

BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules

iShares Global Healthcare

BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules

09988

00883

00467

00632

09903

09660

02865

On March 10, 2026, Hong Kong stocks collectively rose during the trading session, with the Hang Seng Index up 1.19% at 25,709.86 points, and the Hang Seng Tech Index approaching the 5,000-point mark. The internet content and retail sectors led the gains, with major stocks like Tencent Holdings, Alibaba, and JD.com significantly rising, boosting market risk appetite. Meanwhile, the oil and gas sector was pressured by weakening oil prices, with China National Offshore Oil Corporation falling over 2%. On the macro front, employment and foreign exchange remained stable, with funds focusing on the pace of domestic demand recovery

- As of March 10, 2026, Hong Kong stocks rose collectively, with the Hang Seng Index gaining 1.19% to 25,709.86 points amidst improved risk appetite, yet falling short of breaking through previous highs.  
- Key sectors included internet content, where Tencent increased by 3.10%, and retail, reflected by gains from Alibaba and JD.com, while oil and gas stocks fell sharply due to declining international prices.  
- Macroeconomic indicators showed stability in forex reserves and unemployment, prompting investor focus on retail sales and manufacturing for potential growth opportunities.

BABA-W

CNOOC

UNITEDENERGY GP

CHK OIL

ILUVATAR COREX

HORIZONROBOT-W

DRINDA

BABA 2x Long Daily ETF - GraniteShares

KraneShares 2x Long BABA Daily ETF

Tencent

Tencent Holdings Limited

Hong Kong Stock Market Update | Hang Seng Index rises 1.19%, Tencent and Alibaba lead the market

CICC released a research report stating that Beigene's performance last year met expectations, with revenue of USD 5.343 billion, a year-on-year increase of 40%. Product revenue was USD 5.282 billion, and GAAP net profit was USD 287 million. Although net profit was slightly below expectations, mainly due to one-time equity investment impairment and non-recurring tax impacts in the fourth quarter, the adjusted full-year net profit met expectations. CICC lowered its revenue forecast for 2026 by 2.7%, maintained its profit forecast at USD 610 million, and introduced a profit forecast for 2027 at USD 870 million for the first time, maintaining an "outperform" rating with a target price of HKD 250 for H shares

AASTOCKS

In "Major Banks," China International Capital Corporation: Beigene's performance last year met expectations, maintaining an "Outperform Industry" rating

The Citigroup research report pointed out that Beigene's performance in the fourth quarter of 2025 was mixed, with sales increasing by 32.8% year-on-year, exceeding market expectations, but net profit fell short of expectations due to a one-time impairment. Management expects sales in 2026 to be between USD 6.2 billion and USD 6.4 billion, representing an annual growth of approximately 20%. Based on performance, the target price has been adjusted: the Hong Kong stock price has been lowered from HKD 288 to HKD 286.2, the US stock price from USD 491.2 to USD 485.1, and the A-share price from CNY 423.4 to CNY 384.5, maintaining an "outperform" rating

Direxion S&P Biotech Bear 3X

In "The Big Banks," Citigroup lowered the target price for Beigene to 286.2 yuan, with last quarter's net profit falling short of expectations

Jiangyin International released a report stating that BeOne Medicines' sales of Zebutini reached USD 1.1 billion in the fourth quarter of last year, a year-on-year increase of 38%. The gross profit margin improved to 90.5%, and non-GAAP net profit surged to USD 225 million. The company expects revenue of USD 6.2 billion to USD 6.4 billion in 2026, with GAAP operating expenses of USD 4.7 billion to USD 4.9 billion. The company focuses on chronic lymphocytic leukemia, other hematological malignancies, solid tumors, and inflammation/immunity fields, slightly lowering its earnings forecast for 2026 to 2027, with a target price reduced to HKD 229.2, maintaining a "Buy" rating

"Large Banks" CMB International: Beigene's product sales were strong last season, with slight fluctuations on the profit side

Citi raised the target price for Beigene to $430, with a rating of "Buy." The report pointed out that Beigene will continue to maintain its dominance in the chronic lymphocytic leukemia field and is expected to expand its market share. Total revenue is expected to reach $5.3 billion by 2025, with free cash flow of approximately $942 million. Management's revenue guidance for 2026 is between $6.2 billion and $6.4 billion, indicating strong growth potential

Citigroup raises the target price of Beigene to $430, rating it as "Buy"

Bank of America Securities raised the target price for Beigene to 243.83 yuan, expecting total revenue to grow by 40% to 5.34 billion USD in 2025, achieving GAAP profitability for the first time with a net profit of 286.9 million USD. BRUKINSA is the main growth driver, with global sales increasing by 49% to 3.9 billion USD in 2022. Management expects total revenue to be between 6.2 billion and 6.4 billion USD in 2026. The firm reiterated its "Buy" rating, supported by the continued growth of BeiYueZe and multiple pipeline catalysts

According to "The Big Bank," Bank of America Securities raised the target price for Beijie Shenzhou to 243.83 yuan, driven by continuous growth in its main products

01801

03692

Hong Kong-listed Chinese pharmaceutical companies are poised for profitability due to rising drug sales and lucrative licensing deals. Innovent Biologics expects its first full-year profit of 984 million yuan in 2025, driven by a 45% revenue increase. BeOne reported a net profit of US$286.93 million, fueled by its successful blood cancer drug Brukinsa. Other firms like Jiangsu Hengrui and Hansoh Pharma are also projected to see significant profit growth. The trend of out-licensing early-stage drugs to global firms is strengthening, with investors increasingly interested in China's healthcare sector.

SCMP

INNOVENT BIO

HANSOH PHARMA

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Guotai Haitong has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$212.09, while the stock closed at HK$192.30. The analyst consensus is a Strong Buy with an average target of HK$244.52, indicating a potential upside of 27.16%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00.

Guotai Haitong Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

$Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticalsmp.weixin.qq.com/s/gihUP-...

当前环境异常，完成验证后即可继续访问。

Zai Lab

ZAI LAB

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

TENCENT-R

Tencent HK SDR 10to1

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

RemeGen

WUXI BIO

WuXi Biologics

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

ZA ONLINE

BITFIRE GROUP

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks opened high and moved higher, with technology stocks and pharmaceutical stocks rising together. The technology index rose 2.35%, Tencent Music surged more than 15% after earnings, and Alibaba rose more than 4%.

BABA-WR

Alibaba HK SDR 5to1

Alibaba

Hong Kong stock hot trading (8.13)｜ Hong Kong technology stocks fully exploded, Tencent hit a four-year high, Alibaba surged over 4%

BIBEONE@EC2610A(27274.HK)

BIBEONE@EC2610A Stock Performance Chart

Hong Kong Stock Midday Review | Hang Seng Index Approaches 25,000 Points, Strong Performance in Dining Retail with Haidilao Up 6.47%

Achieves Annual Profitability for the First Time! BeiGene Reports 2025 Net Profit of $287 Million, Revenue Surges 40% to $5.34 Billion | Earnings Watch

Beijing Beone Medicines: Revenue of USD 5.343 billion in 2025, a year-on-year increase of 40.2%; net profit of USD 287 million, compared to a net loss of USD 645 million in the same period last year

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

BeOne Medicines Updates on Employee Share Purchase Plan Uptake